Alder inks $250 million deal and preps FDA filing after migraine drug trial posts strong results

The developments keep Alder in the running for a market opportunity worth more than $10 billion.

Source: bizjournals.com Health Care:Biotechnology headlines - January 8, 2018 Category: Biotechnology Authors: Casey Coombs Source Type: news